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 8.1 The somatic nervous system 
The somatic/voluntary nervous system is distinguishable from the branches of the autonomic 
nervous system by having no ganglia.  The nerves arising from the spinal cord release 
acetylcholine onto NM, the nicotinic receptors associated with skeletal muscle (Figure 8.1). 
 
Figure 8.1 Neuromuscular junction (Copyright QUT, Sheila Doggrell) 
 
Acetylcholine receptors were initially divided on their basis of responses to nicotine and 
muscarine, into those that responded to nicotine, nicotinic receptors, and those that responded 
to muscarine, muscarinic receptors.    The NN receptors are found at the autonomic ganglia, 
adrenal medulla and within the central nervous system.  The NM receptors are found on 
skeletal muscle innervated by the somatic nervous system.  The NM receptor can be 




In order to stimulate NM receptors, anticholinesterases are used to prevent the breakdown of 
acetylcholine, and build up the concentrations of acetylcholine at the NM receptors.  This was 
discussed in eChapter 3. 
 
 8.3 Neuromuscular blockers 
There are two types of neuromuscular blockers, non-depolarizing (which are competitive 
antagonists) and depolarizing antagonists.  The non-depolarizing (competitive) antagonists 
have no effect alone, but prevent Ach binding to NM-receptors.  The first non-depolarizing 
antagonist was tubocurarine.  Tubocurarine was known as curare and was used on in arrow 
heads to immobilize animals.  Newer examples of non-depolarizing neuromuscular blockers 
include mivacurium, vecuronium, and rocuronium.  Tubocararine is long acting, and 
difficult to fully reverse.  The long acting non-depolarizing agents have been replaced by 
intermediate (vecuronium) and short-acting neuromuscular blockers (mivacurium).  
Vecuronium and mivacurium have a clinical duration of 60-90 minutes and 12-18 minutes, 
respectively, whereas rocuronium has a rapid onset (1-2 minutes) and intermediate duration 
(30-60 minutes). 
 
The depolarizing neuromuscular blocker is succinylcholine (also known as 
suxamethonium), which initial causes depolarization/agonism with small contractions of the 
skeletal muscle.  This is followed by causing persistent depolarization, which prevents the 
activation by acetylcholine and the skeletal muscle remains flaccid (relaxed).  The effects of 
succinylcholine usually last for 5 minutes as it is rapidly metabolised by 
pseudocholinesterase.  One in 3000 people are deficient in pseudocholinesterase, and in these 
people the effects of succinylcholine lasts for 20 h, as it is slowly metabolised. 
 
The neuromuscular blockers are used to cause paralysis of skeletal muscle.  The last muscles 
to be affected are the intercostal and diaphragm muscles.  This means that there can be 
paralysis of other skeletal muscles without paralysis of respiration, which is good as paralysis 
of respiration can be deadly.  The neuromuscular blockers are quaternary N
+
 compounds.  As 
discussed in eChapter 1, quaternary N
+
 compounds are poorly absorbed after oral 
administration, and are used intravenously. 
 
The main clinical use of neuromuscular blockers is an adjuvant in surgical anaesthesia to 
cause relaxation of skeletal muscle.  The neuromuscular blockers are also used to cause 
relaxation of skeletal muscle in intensive care.  The use of neuromuscular blockers is limited 
to anesthesiologists or other clinicians with extensive training in their use, and the choice of 
agent depends on duration of paralysis required. 
 
The neuromuscular blockers have to be given to cause relaxation of muscles in arms and legs, 
without paralysing respiration muscle.  When too much neuromuscular blocker has been 
given, it is essential to understand the interaction with anti-cholinesterases.  Non-
depolarizing/competitive reversible antagonism can be overcome by increasing the 
concentrations of acetylcholine in the synapse with an anti-cholinesterase (e.g. neostigmine).  
Ach will compete with non-depolarising agent for receptor and displace it, and thus decrease 
the effect of the antagonist.  Depolarizing antagonism cannot be overcome by increasing the 
concentrations of acetylcholine in the synapse with an anti-cholinesterase. Ach will cause 
further depolarisation and make the block worse  
 
 8.4 Botox 
Anaerobic bacterium Clostridium botulinum produces several toxins including botulinum 
toxin A (commonly known as Botox).  Botox blocks the release of acetylcholine from all 
cholinergic nerve endings.  This means that Botox inhibits the release of acetylcholine from 
the preganglionic nerves of the autonomic nervous system (both parasympathetic nervous 
system and sympathetic nervous system), from the postganglionic nerves of parasympathetic 
NS, and from the somatic nervous system.  Thus, Botox inhibits the actions of the autonomic 
and somatic nervous system.  The blockade with Botox lasts 3 to 4 months, and restoration of 
function requires nerve growth.  Clinically, Botox is used to treat muscle spasms in a variety 
of conditions.  Botox is best known for its use in cosmetic surgery.  Because Botox is 
extremely toxic, miniscule amounts are used and with intramuscular administration, there is 
only a local effect. 
 
